{"Clinical Trial ID": "NCT00494481", "Intervention": ["INTERVENTION 1:", "Vandetanib Plus Docetaxel", "Vandetanib 100 mg plus docetaxel", "INTERVENTION 2:", "Placebo Plus Docetaxel", "- placebo plus docetaxel"], "Eligibility": ["Incorporation criteria:", "Women with histological/cytological confirmation of breast cancer.", "Subjects with measurable injury or bone damage", "- Exclusion criteria:", "Previous radiation therapy within 6 weeks", "Important heart events, arrhythmias or other heart conditions"], "Results": ["Performance measures:", "Number of patients with disease progression event", "Number of patients with objective progression of disease or death (by any cause in the absence of objective progression)", "Time frame: Evaluations of RECIST tumours performed during screening (within 3 weeks prior to the first dose) and then according to clinical practice of the site until objective progression. The only additional mandatory RECIST evaluation is at the cut-off point.", "Results 1:", "Title of the arm/group: Vandetanib Plus Docetaxel", "Description of the arm/group: vandetanib 100 mg plus docetaxel", "Total number of participants analysed: 35", "Type of measurement: Number", "Unit of measure: Participants 24", "Results 2:", "Title of the arm/group: Placebo Plus Docetaxel", "Description of the arm/group: placebo plus docetaxel", "Total number of participants analysed: 29", "Type of measurement: Number", "Unit of measure: Participants 18"], "Adverse Events": ["Undesirable Events 1:", "Total: 14/33 (42.42 per cent)", "Neutropenia 4/33 (12.12 per cent)", "Febrile Neutropenia 3/33 (9.09%)", "Granulocytopenia 0/33 (0.00 %)", "Atrial fibrillation 1/33 (3.03%)", "Vertigo 1/33 (3.03%)", "Keratite 1/33 (3.03%)", "Diarrhoea 3/33 (9.09%)", "- Conaction 0/33 (0.00 %)", "Ileus 1/33 (3.03%)", "Nausea 1/33 (3.03%)", "Stomatitis 1/33 (3.03%)", "Asthenia 1/33 (3.03%)", "Fatigue 1/33 (3.03%)", "Adverse Events 2:", "Total: 12/29 (41.38 per cent)", "Neutropenia 2/29 (6.90 per cent)", "Febrile Neutropenia 1/29 (3.45%)", "Granulocytopenia 1/29 (3.45%)", "Atrial fibrillation 1/29 (3.45%)", "Vertigo 0/29 (0.00 %)", "Keratite 0/29 (0.00 %)", "Diarrhoea 0/29 (0.00 %)", "Colite 1/29 (3.45 per cent)", "Ileus 0/29 (0.00 per cent)", "- Nausea 0/29 (0.00 per cent)", "- Stomatitis 0/29 (0.00 %)", "Asthenia 0/29 (0.00 %)", "- Fatigue 0/29 (0.00 %)", "Pyrexia 1/29 (3.45%)"]}